G01N 2333/91148
Transferring other glycosyl groups
Official title: transferring other glycosyl groups (2.4.99)
G01N2333/91148 (Transferring other glycosyl groups) appears on 15 US grants and 29 published applications in this corpus.
Search patents in G01N- Granted patents
- 15
- Published applications
- 29
- Assignees
- 17
- Inventors
- 53
- Latest grant
- 19 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 1 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 1 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 2 | 1 |
| 2016 | 1 | 4 |
| 2017 | 1 | 1 |
| 2018 | 1 | 2 |
| 2019 | 1 | 3 |
| 2020 | 0 | 2 |
| 2021 | 2 | 1 |
| 2022 | 2 | 3 |
| 2023 | 1 | 1 |
| 2024 | 2 | 2 |
| 2025 | 1 | 1 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies19 Aug 2025US 12,391,765 B2Takeda Pharmaceutical Company Limited
- Glucose sensors and methods of use thereof19 Nov 2024US 12,146,883 B2Biocapital Holdings, LLC
- IgG epitope and applications thereof as a drug target3 Sep 2024US 12,077,602 B2Beijing SIG Biopharmaceutical Technology Co., Ltd.
- Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies28 Mar 2023US 11,613,586 B2Takeda Pharmaceutical Company Limited
- Sialyltransferase ST3GAL6 as a marker for multiple myeloma8 Feb 2022US 11,242,566 B2National University of Ireland, Galway
- Antibodies against human cd384 Jun 2026US 2026/0152566 A1Genmab A/S
- Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies19 Mar 2026US 2026/0078199 A1Takeda Pharmaceutical Company Limited
- Glucose sensors and methods of use thereof30 Jan 2025US 2025/0035637 A1Biocapital Holdings, LLC
- Antibodies against cd38 for treatment of multiple myeloma11 Jul 2024US 2024/0228662 A9Genmab A/S
- Antibodies against cd38 for treatment of multiple myeloma25 Apr 2024US 2024/0132620 A1Genmab A/S
Most cited
By later US patents
- Antibodies against CD38 for treatment of multiple myeloma94US 7,829,673 B2Genmab A/S · 2010
- Antibodies against human CD3812US 9,249,226 B2Genmab A/S · 2016
- Antibodies against human CD388US 9,944,711 B2Genmab A/S · 2018
- Methods and compositions for identifying leukemic stem cells3US 10,222,376 B2The Charlotte-Mecklenburg Hospital Authority · 2019
- Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies2US 11,613,586 B2Takeda Pharmaceutical Company Limited · 2023